Baum, Richard P.

Phase 3 Trial of 177 Lu-Dotatate for Midgut Neuroendocrine Tumors

Strosberg, J., El-Haddad, G., Wolin, E., Hendifar, A., Yao, J., Chasen, B., Mittra, E., Kunz, P. L., Kulke, M. H., Jacene, H., et al. (2017) · New England Journal of Medicine

Neuroendocrine Tumor Research AdvancesRadiopharmaceutical Chemistry and Applications

Cited by 3,308

Long-term tolerability of PRRT in 807 patients with neuroendocrine tumours: the value and limitations of clinical factors

Bodei, L., Kidd, M., Paganelli, G., Grana, C. M., Drozdov, I., Cremonesi, M., Lepensky, C., Kwekkeboom, D. J., Baum, R. P., Krenning, E. P., et al. (2015) · European Journal of Nuclear Medicine and Molecular Imaging

Neuroendocrine Tumor Research AdvancesRadiopharmaceutical Chemistry and Applications

Cited by 465

Results and adverse events of personalized peptide receptor radionuclide therapy with 90Yttrium and 177Lutetium in 1048 patients with neuroendocrine neoplasms

Baum, R. P., Kulkarni, H. R., Singh, A., Kaemmerer, D., Mueller, D., Prasad, V., Hommann, M., Robiller, F. C., Niepsch, K., Franz, H., et al. (2018) · Oncotarget

Neuroendocrine Tumor Research AdvancesRadiopharmaceutical Chemistry and Applications

Cited by 141

First-in-Humans Study of the SSTR Antagonist 177Lu-DOTA-LM3 for Peptide Receptor Radionuclide Therapy in Patients with Metastatic Neuroendocrine Neoplasms: Dosimetry, Safety, and Efficacy

Baum, R. P., Zhang, J., Schuchardt, C., Müller, D., & Mäcke, H. (2021) · Journal of Nuclear Medicine

Neuroendocrine Tumor Research AdvancesRadiopharmaceutical Chemistry and Applications

Cited by 127

Alpha-peptide receptor radionuclide therapy using actinium-225 labeled somatostatin receptor agonists and antagonists

Shi, M., Jakobsson, V., Greifenstein, L., Khong, P.-L., Chen, X., Baum, R. P., & Zhang, J. (2022) · Frontiers in Medicine

Radiopharmaceutical Chemistry and ApplicationsNeuroendocrine Tumor Research Advances

Cited by 68

Therapy-related myeloid neoplasm after peptide receptor radionuclide therapy (PRRT) in 1631 patients from our 20 years of experiences: Prognostic parameters and overall survival

Chantadisai, M., Kulkarni, H. R., & Baum, R. P. (2021) · European Journal of Nuclear Medicine and Molecular Imaging

Acute Myeloid Leukemia ResearchRadiopharmaceutical Chemistry and Applications

Cited by 43

225Ac-DOTATOC-Targeted Somatostatin Receptor α-Therapy in a Patient With Metastatic Neuroendocrine Tumor of the Thymus, Refractory to β-Radiation.

Zhang, J., Kulkarni, H. R., & Baum, R. P. (2021) · Clinical Nuclear Medicine

Neuroendocrine Tumor Research AdvancesRadiopharmaceutical Chemistry and Applications

Cited by 19

Intraoperative Somatostatin Receptor Detection After Peptide Receptor Radionuclide Therapy with 177Lu- and 90Y-DOTATOC (Tandem PRRNT) in a Patient with a Metastatic Neuroendocrine Tumor

Todorović-Tirnanić, M., Kaemmerer, D., Prasad, V., Hommann, M., & Baum, R. P. (2013) · Recent Results in Cancer Research

Neuroendocrine Tumor Research AdvancesRadiopharmaceutical Chemistry and Applications

Cited by 10